Year 2018 / Volume 110 / Number 10
Original
Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals

621-628

DOI: 10.17235/reed.2018.5605/2018

Javier Mar, Oliver Ibarrondo, Iván Martínez-Baz, Regina Juanbeltz, Ramón San Miguel, Itziar Casado, Arantzazu Arrospide, Jesús Castilla,

Abstract
The high initial cost of antivirals against hepatitis C prompted development of the "Strategic Plan for Tackling Chronic Hepatitis C in the Spanish National Health System”. The objective of this study was the economic evaluation of the first two years of its application in Navarre, Spain. The change in the natural history of hepatitis C produced by the sustained virological response (SVR) was compared to an alternative without treatment and modeled with patient-level data. By means of a discrete events simulation model, the cost-effectiveness and the budget impact analysis of the treatment program were measured from the perspective of the Navarre Health Service. Of 656 patients treated, 98% had SVR. The average cost of the treatments was 18,743 euros per patient. The incremental cost-effectiveness ratio (ICER) with discount was 5,346 euros per quality-adjusted life years, which became more efficient as the stage of fibrosis increased until it reached levels of dominance in stage 4 fibrosis. The associated costs for chronic liver disease decreased as the benefit of the treatment was expressed. The implementation of the Strategic Plan is cost-effective, with an ICER well below the threshold, since the cost of treatment is largely compensated by savings in long-term health expenditure. The budgetary impact foresees a net saving from the third year on. The two key parameters were the decrease in the price of the treatment and the SVR in nearly 100% of the patients.
Share Button
New comment
Comments
No comments for this article
References
1. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 2014;21 Suppl 1:34–59.
2. San Miguel R, Gimeno-Ballester V, Blázquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 2015;64:1277–88.
3. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002 Nov;36(5 Suppl 1):S237-44.
4. McHutchison JG, Ware JE Jr, Bayliss MS, et al; Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol. 2001 Jan;34(1):140-7.
5. Blázquez-Pérez A, San Miguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. PharmacoEconomics 2013;31:919–31. doi:10.1007/s40273-013-0080-3.
6. Hézode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014 Jul;147:132-142.e4.
7. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. N Engl J Med 2013;368:1878–87.
8. Secretaría General de Sanidad y Consumo. Plan estratégico para el abordaje de la hepatitis C en el sistema nacional de salud. Ministerio de Sanidad, Servicios Sociales y Consumo; 2015. https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/docs/plan_estrategico_hepatitis_C.pdf Acceso 01/03/2018.
9. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014 Jan-Feb;17(1):5-1.
10. Vallejo-Torres L, García-Lorenzo B, Castilla I, et al. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How? Value Health 2016;19:558–66.
11. Gimeno-Ballester V, Mar J, O'Leary A, et al. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert Rev Gastroenterol Hepatol. 2017 Jan;11(1):85-93.
12. Mar J, Mar-Barrutia L, Gimeno-Ballester V, et al. Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis.Med Clin (Barc). 2016 Jan 15;146(2):61-4.
13. Garrison LP Jr, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007 Sep-Oct;10(5):326-35.
14. Aguinaga A, Díaz-González J, Pérez-García A, et al. The prevalence of diagnosed and undiagnosed hepatitis C virus infection in Navarra, Spain, 2014-2016. Enferm Infecc Microbiol Clin 2017 Jan 19. pii: S0213-005X(16)30401-3. doi: 10.1016/j.eimc.2016.12.008.
15. Karnon J, Stahl J, Brennan A, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4. Med Decis Making 2012;32:701–711.
16. López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010 Oct;11(5):513-20.
17. Arrospide A, Rue M, van Ravesteyn NT, et al. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis. BMC Cancer. 2016; 16:344.
18. Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015;41:544–63.
19. Mar J, Martínez-Baz I, Ibarrondo O, et al. Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments. Expert Rev Gastroenterol Hepatol 2017;0:1–10.
20. Mar J, Antoñanzas F, Pradas R, et al. Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: una guía práctica. Gac Sanit. 2010;24:209-14.
21. Sawinski D, Forde KA, Locke JE, et al. Race but not Hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice. Kidney Int 2017. pii: S0085-2538(17)30612-9.
22. Román R, Comas M, Hoffmeister L, et al. Determining the lifetime density function using a continuous approach. J Epidemiol Community Health. 2007 Oct;61(10):923-5.
23. Liu S, Cipriano LE, Holodniy M, et al. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012;156:279–90.
24. RESOLUCIÓN 626/2014, de 5 de junio, del Director Gerente del Servicio Navarro de Salud-Osasunbidea, por la que se actualizan las tarifas por los servicios prestados por el Servicio Navarro de Salud-Osasunbidea. 2014. https://www.navarra.es/home_es/Actualidad/BON/Boletines/2014/133/ Acceso 01/03/2018.
25. Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55(9):1332-8.
26. Salomon JA, Weinstein MC, Hammitt JK, et al. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002;156:761–73.
27. Sacristán JA, Oliva J, Del Llano J, et al. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 2002;16:334-43
28. Chhatwal J, He T, Lopez-Olivo MA. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. Pharmacoeconomics. 2016;34(6):551-67.
29. Juanbeltz R, Goñi Esarte S, Úriz-Otano JI, et al. Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgrad Med. 2017;129(4):476-483.
30. Brosa M, Gisbert R, Rodríguez Barrios JM, et al. Principios, métodos, y aplicaciones del análisis del impacto presupuestario en sanidad. Pharmacoecon Spanish Res Artic 2005;2:65–79.
31. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–72.
32. Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics. 2008;26(2):131-48.
Citation tools
Mar J, Ibarrondo O, Martínez-Baz I, Juanbeltz R, San Miguel R, Casado I, et all. Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals. 5605/2018


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1075 visits.
This article has been downloaded 242 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 16/03/2018

Accepted: 17/04/2018

Online First: 23/07/2018

Published: 01/10/2018

Article revision time: 26 days

Article Online First time: 129 days

Article editing time: 199 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology